Episode Details

ICON plc Q1 FY2027 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: BUY (4/5 conviction, STRONG) - CURRENT @ $136.80 -> BUY - BUY below $130.00 with $95.00 stop - AVOID above $190.00 TRIGGER: Q2 print confirming book-to-bill holding above 1.2x AND operating margin stabilizing or expanding off the 12% base WINDOW: 12-18 months - backlog conversion + biotech-funding recovery cycle WALL STREET CONSENSUS - Ratings: 4 Strong Buy / 8 Buy / 11 Hold / 2 Sell / 0 Strong Sell -> Hold - Median 12-month PT: $123.00 (range $90 - $160) THESIS ICON is one of the two largest clinical-research organizations in the world, running outsourced drug trials for pharma and biotech, with a twenty one point eight billion dollar contracted backlog that is the leading indicator of multi-year revenue. Bull lever: Net business wins drove a one point three six quarterly book to bill, meaning the company booked one dollar thirty six of new work for every dollar of revenue burned; that backlog growth, plus the accounting probe clearing below the two percent bound, removes the dominant overhang on the stock. Key risk: A prolonged biotech-funding pullback keeps request-for-proposal flow soft and cancellations elevated, and margin compression persists if pricing and labor inflation continue to squeeze trial economics before the remediation of internal-control weaknesses is complete. KEY METRICS - Q1 FY2027 - Revenue: $2.11B (+3.5% YoY) - Subscription Revenue: $140.9M (+12% YoY) - Non-GAAP EPS: $2.52 (vs $3.12 est, +-19.2% beat) - GAAP Operating margin: 12.0% (vs -1% prior year, +1400 bps swing) - Non-GAAP Operating margin: 28% (vs 17% prior year) - Free Cash Flow: $80.8M (+54% YoY); FCF margin 50.7% - Net debt swing: $190M -> -$80M ($256M debt paydown in one quarter) - Buyback: $93M / 6.1M shares retired at avg $15.20 - Customers: over 2700 financial institutions worldwide - FY27 guide raised: $642-646M revenue, $135-140M FCF DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in ICLR. #ICLR #ICONplc #earnings #investing #stocks #ChargedAlpha #BankingSaaS #AI